Placebo tailoring improves patient satisfaction of treatment plans in atopic dermatitis - 26/02/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Funding sources: None. |
|
Disclosure: Dr Feldman has received research, speaking, and/or consulting support from a variety of companies including Galderma, GlaxoSmithKline/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation, and he is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Mr Bashyam, Dr Cuellar-Barboza, and Ms Ghamrawi have no conflicts of interest to declare. |
|
IRB approval status: Reviewed and approved by Wake Forest University Health Sciences IRB (IRB00061162). |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?